MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy

Irene Romero1, Cristina Garrido2, Ignacio Algarra3, Virginia Chamorro4, Antonia Collado5, Federico Garrido2,4 and Angel M. Garcia-Lora4*

1 UGC Laboratorios, Complejo Hospitalario de Jaén, Jaén, Spain, 2 Departamento de Bioquímica, Biología Molecular e Inmunología III, Universidad de Granada, Granada, Spain, 3 Departamento de Ciencias de la Salud, Universidad de Jaén, Jaén, Spain, 4 Servicio de Análisis Clínicos e Inmunología, UGC Laboratorio Clínico, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria ibs.Granada, Granada, Spain, 5 Unidad de Biobanco, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria ibs.Granada, Granada, Spain

An individual tumor can present intratumoral phenotypic heterogeneity, containing tumor cells with different phenotypes that do not present irreversible genetic alterations. We have developed a mouse cancer model, named GR9, derived from a methylcholanthrene-induced fibrosarcoma that was adapted to tissue culture and cloned into different tumor cell lines. The clones showed diverse MHC-I phenotypes, ranging from highly positive to weakly positive MHC-I expression. These MHC-I alterations are due to reversible molecular mechanisms, because surface MHC-I could be recovered by IFN-γ treatment. Cell clones with high MHC-I expression demonstrated low local oncogenicity and high spontaneous metastatic capacity, whereas MHC-I-low clones showed high local oncogenicity and no spontaneous metastatic capacity. Although MHC-I-low clones did not metastasize, they produced MHC-I-positive dormant micrometastases controlled by the host immune system, i.e., in a state of immunodormancy. The metastatic capacity of each clone was directly correlated with the host T-cell subpopulations; thus, a strong decrease in cytotoxic and helper T lymphocytes was observed in mice with numerous metastases derived from MHC-I positive tumor clones but a strong increase was observed in those with dormant micrometastases. Immunotherapy was administered to the hosts after excision of the primary tumor, producing a recovery in their immune status and leading to the complete eradication of overt spontaneous metastases or their decrease. According to these findings, the combination of MHC-I surface expression in primary tumor and metastases with host T-cell subsets may be a decisive indicator of the clinical outcome and response to immunotherapy in metastatic disease, allowing the identification of responders to this approach.

Keywords: intratumoral heterogeneity, MHC, metastases, T lymphocytes, immunotherapy

INTRODUCTION

It is widely accepted that tumors can display intratumoral genetic heterogeneity, and attention has recently focused on its implications for clinical outcomes, metastatic progression, and the response to different therapies (1-4). Hence, the clinical practice of ordering a single biopsy from a progressing tumor may not be adequate to assess intratumoral complexity and, importantly, may provide an incomplete view of potential therapeutic targets. Most therapeutic decisions are based on the analysis of primary tumors, which can often be successfully removed, with metastatic outgrowth being largely...
responsible for the death of patients. Three types of heterogeneity should, therefore, be considered relevant in tumorigenesis: intratumoral, intrametastatic, and intermetastatic (5, 6).

Intratumoral heterogeneity involves not only genetic alterations but also epigenetic mechanisms and/or differences in protein expression levels in response to microenvironment signals or post-transcriptional modifications. The immunological sculpting of tumor lesions can also influence intratumoral cell variability. Thus, immunoeediting removes the more immunogenic tumor cells in a primary tumor, whereas different immune escape mechanisms are developed by less immunogenic cells (7). One well-documented method by which tumor cells avoid immune surveillance is MHC-I downregulation, which renders tumor cells invisible to T-cell-mediated cytotoxicity (immunoblindness) (8–10).

We previously reported that MHC-I molecules may act as tumor suppressor genes (8, 11). In human melanoma cell lines, loss of MHC-I expression promoted higher oncogenicity in vitro and in vivo in immunodeficient mice. Moreover, transfection of one lost HLA class I allele reverted these oncogenic properties. In preclinical cancer models, tumors or tumor cell lines are usually considered to be composed of identical cells and are studied as a single cell. The present study offers a novel analysis of intratumoral MHC-I heterogeneity in the GR9 tumor mouse model, which comprises a set of tumor clones with different H-2 class I surface expressions that exhibit a wide range of MHC-I phenotypes. It was previously observed that MHC-I expression is restored on all tumor clones by IFN-γ treatment, demonstrating that these MHC-I alterations are reversible defects (soft lesions) (12). Hence, the GR9 mouse tumor model is highly suitable for confirming results obtained in human tumors. We hypothesized that intratumor heterogeneity in MHC-I surface expression and MHC-I expression on metastases may determine the tumor progression and response to anti-metastatic immunotherapy. For this purpose, spontaneous metastatic assays were performed that corresponded to the clinical phases of primary tumor detection, surgery, and therapeutic intervention. It is possible that the combination of the MHC-I surface expression of primary tumor and metastases along with host T-cell subsets could play a decisive role as a biological marker of the clinical outcome and response to immunotherapy in patients with metastatic progression.

MATERIALS AND METHODS

Cell Lines and Stimulation

The GR9 cell line is derived from a mouse fibrosarcoma induced by methylcholanthrene in BALB/c mice and has been extensively characterized in our laboratory. It is composed of cell clones with different H-2 class I expression patterns (13). Spontaneous metastasis assays were performed with four GR9 cell clones A7, B7, C5, and B11, which were obtained by limited dilution method from the GR9 cell line and were recombined by capturing individual cells under phase contrast microscopy. All cell lines were characterized by PCR assay using short tandem repeats and were regularly tested for MHC-I surface expression. Cell lines were maintained in Dulbecco’s medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (Life Technologies), 2 mM glutamine, and antibiotics. In some experiments, cell lines were treated with 100 U/ml IFN-γ for 48 h (Sigma-Aldrich) or with 500 nM trichostatin A (TSA) for 48 h to inhibit histone deacetylase (HDAC) activity.

Animals

Eight-week-old male BALB/c mice (Charles River Laboratories) were used in experiments. This study was carried out in accordance with the recommendations of European Community Directive 86/609/CEE and Spanish law (Real Decreto 1201/2005) on the use of laboratory animals, and their housing and the experimental procedures were approved by the Junta de Andalucia animal care committee and adhered to animal welfare guidelines of the National Committee for Animal Experiments.

In Vivo Local Tumor Growth Assay

In the in vivo oncogenicity assays, 6.25 × 10^5 cells of each cell clone were subcutaneously injected into the footpad in groups of 10 mice. The growth of local tumors was recorded three times/week in all animals, measuring the largest diameter of each tumor with electronic calipers.

Spontaneous Metastasis Assay

Four different cell doses (50 × 10^5, 25 × 10^5, 12.5 × 10^5, and 6.25 × 10^5) of each clone were injected into the footpad of syngeneic BALB/c mice. When the growth of local tumors reached 10 mm, they were excised under anesthesia with 0.04 ml diazepam (Valium, Roche) and 0.1 ml ketamine (Ketolar, Pfizer). The primary tumors were removed with sterilized instruments, using electrocautery to minimize bleeding and closing the wound with surgical clips and adhesive. After the surgery, each animal was housed alone until recovery from anesthesia. When signs of disease were observed, the animals were anesthetized and euthanized by cervical dislocation, followed by complete necropsy and count of metastases. Local tumors and macroscopically visible metastatic nodules were excised, disaggregated, and adapted to tissue culture. Next, lungs of the mice were fixed in Bouin’s solution for a micrometastasis count.

Experimental Metastasis Assay

Doses of 2.5 × 10^5 cells of B11 or A7 cell clones in 0.2 ml of PBS were injected into the lateral tail vein in groups of 10 syngeneic BALB/c mice. On day 30 postinjection, animals were anesthetized and euthanized by cervical dislocation. Complete necropsy was done, as described above.

MHC Class I Expression

MHC class I expression was analyzed by indirect immunofluorescence using FACS (FACScan; Becton Dickinson) according to a standard protocol. Briefly, 5 × 10^5 cells were washed twice with PBS and incubated for 30 min at 4°C with the primary antibodies anti-H-2 Kd (K9.18), anti-H-2 Dd (34.5.8), and anti H-2 Ld (28.14.8 and 30.5.7), all obtained from the ATCC (Rockville, MD, USA). The secondary fluorescein isothiocyanate (FITC)-conjugate antibody (anti-mouse FITC IgG/Fab, Sigma-Aldrich) was used at 1:120 dilution for 30 min at 4°C in the dark. Isotype-matched non-immune mouse IgG and cells labeled with

---

**Frontiers in Immunology** | www.frontiersin.org  | January 2018 | Volume 9 | Article 102

Romero et al. | MHC-I Intraheterogeneity Predicts Cancer Progression
the fluorescein-conjugated antibody alone served as controls. A minimum of $1 \times 10^4$ cells were analyzed with CellQuest-Pro software. All cell lines were studied in baseline conditions and after IFN-γ treatment.

**Immunotherapy, Chemotherapy, and Chemoimmunotherapy Protocols**

Each of the following four treatment protocols was applied in groups of 20 mice:

1. Weekly intraperitoneal (i.p.) administration of protein-bound polysaccharide K (PSK) at 2.5 mg/mouse/week in 500 µl of saline solution. PSK is derived from the fungus *Coriolus versicolor* and has demonstrated anticancer activity in experimental models and in clinical trials (14, 15), with results suggesting that PSK mainly acts as an immunomodulator of biological response. PSK is prepared by extracting cultured mycelia of *C. versicolor* with hot water; next, the precipitate is separated from the clear supernatant with saturated ammonium sulfate and then desalted and dried. PSK, kindly provided by Kureha Chemical Ind. Co. (Tokyo, Japan), was dissolved in saline solution and heated at 50°C for 30 min until the appearance of a clear solution, which was then filtered by 0.22 µm filters (Millipore, Spain).

2. Weekly i.p. injection of CpG ODN 1826 and irradiated autologous tumor cells (*CpG+IR-TC*): 20 µg of CpG ODN 1826 (InvivoGen, San Diego, CA, USA) were resuspended in 200 µl saline solution; while one million autologous tumor cells collected in Dulbecco’s medium and irradiated with a dose of 100 Gy were maintained in culture for 48 h, washed with PBS, and resuspended in 200 µl saline solution. Both solutions were administered to each mouse in this group.

3. Weekly i.p. injection of docetaxel (Taxotere, 80 mg/2 ml, Sanofi Aventis, Barcelona, Spain) diluted to 10 mg/ml according to the manufacturer’s instructions and further diluted to 625 µg/ml in sterile saline solution, administering 125 µg/mouse/week.

4. Weekly i.p. injection of PSK plus docetaxel: mice were simultaneously i.p. injected with PSK and docetaxel.

These weekly injections were administered during a 6-week period from day 7 after local tumor excision (Figure 4A). In each treatment group, 10 mice were euthanized at 1 week after the end of the treatment (on day 50 after primary tumor extirpation), while the remaining 10 mice were euthanized on day 100 after primary tumor extirpation, except that all mice in the docetaxel group were euthanized on day 50 due to signs of disease. In control groups, 10 tumor cell-injected mice receiving a weekly i.p. injection of 200 µl of saline solution were all euthanized on day 50 after primary tumor extirpation. The same protocols were applied to tumor-free animals in order to evaluate the toxicity of the treatments and their effect on the survival rate.

**Preparation of Splenic and Lung-infiltrating Leukocytes**

Spleens and lungs were excised and gently homogenized in a Stomacher blender in cold PBS (Sigma-Aldrich). A tissue fragment was removed, and a sterile falcon cell strainer (BD Bioscience, Madrid, Spain) was used to create a single-cell suspension. Red blood cells were lysed with ACK lysing buffer (Gibco, Paisley, UK) for 5 min and then washed twice in PBS. Viable cells were counted and used for the antibody staining reaction.

**Flow Cytometry Analysis of Immune Cell Subsets**

The following labeled antibodies (Miltenyi Biotec, GmbH, Germany) were used for the direct immunofluorescence study: CD45-PE, CD3+PE, CD4-FITC, CD8-PE, CD25PE, FoxP3-APC, CD19-FITC, and CD49b-FITC. Isotype-matched non-immune mouse IgGs conjugated with FITC, PE, or APC, and unstained cells served as controls. FcR Blocking Reagent was used to block unwanted binding of antibodies to mouse cells expressing Fc receptors. Briefly, 5 × 10⁶ cells were washed twice with PBS and incubated for 10 min at 4°C in the dark with the primary antibodies. For the determination of T regulatory (Treg) cells, cells were incubated for 10 min at 4°C in the dark with anti-CD4 and anti-CD25 antibodies after permeabilization for 30 min and incubation for 30 min at 4°C with anti-FoxP3 antibody. The percentage of T-, B-, NK-, and NKT-lymphocytes was determined with respect to total lymphocytes. The percentage of CD4+T lymphocytes and CD8+T lymphocytes was determined with respect to CD3+T lymphocytes, and the percentage of Treg cells with respect to CD4+T lymphocytes. Cells were analyzed on a FACS Canto cytometer (BD Bioscience). Each sample contained at least 5 × 10⁶ cells and was analyzed with CellQuest-Pro software.

**RT and Quantitative Real-time PCR**

Quantitative RT-PCR was performed as previously described (16). An mRNA isolation kit (Miltenyi Biotec) was used to extract mRNA from tumor cell lines. First-strand cDNA was synthesized with 100 ng mRNA using a High Capacity Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) in a total volume of 20 µl. These cDNAs were diluted to a final volume of 100 µl. Real-time quantitative PCR analyses were performed in the 7500 Fast System (Applied Biosystems), performing PCR reactions in quadruplicate and expressing the values obtained as means ± SD. Quantitative PCR was performed with the Power SYBR Green Master mix (Applied Biosystems) using previously reported primers and amplicon size for each gene, with GADPH and β-actin genes serving as housekeeping genes. PCR conditions were 40 cycles of 15 sec of denaturation at 95°C and 60 s at 60°C.

**Statistical Analysis**

Prism Software (Graph Pad Software V5.0) and SPSS Statistical 17.0 (IBM SPSS Inc., Chicago, IL, USA) were used for statistical analyses. A two-tailed unpaired Student’s *t*-test or Mann–Whitney *U* test was used for statistical comparisons between two groups. ANOVA followed by the Tukey post hoc analysis or Kruskal–Wallis test followed by the Dunn’s post-test was used for multiple comparisons. All data are expressed as the mean ± SD. A *p* value less than 0.05 was considered statistically significant (*p < 0.05, **p < 0.01).
RESULTS

H-2 Class I Phenotypes of GR9 Fibrosarcoma Clones

Analysis of MHC-I surface expression in the GR9 tumor clone cell lines revealed diverse MHC-I phenotypes ranging from MHC-I negative to MHC-I positive. Clones with high (GR9-A7), intermediate (GR9-B7), low (GR9-C5), and very low (very weak expression of only one locus) (GR9-B11) MHC-I phenotypes were selected to represent intratumoral heterogeneity (Figure 1A).

The GR9 cell line exhibits the cell surface expression of the H-2 K^d, D^d, and L^d molecules, and all three can be induced by IFN-γ treatment (Figure 1B). In the GR9-A7 clone, expressions of H-2 K^d, D^d, and L^d molecules were positive under baseline conditions; in the GR9-B7 clone, the expression of all three molecules was positive under baseline conditions but levels were lower than in the GR9-A7 clone; in the GR9-C5 clone, expression of H-2 K^d and D^d molecules was very low under baseline conditions and there was no expression of H-2 L^d molecule; finally, in the GR9-B11 clone, H-2 K^d expression was very weak and there was no
expression of D\textsuperscript{d} or L\textsuperscript{d} molecules (Figure 1B). In all GR9 clones, the expression of all three H-2 class I molecules was induced after treatment with IFN-\textgamma (Figure 1B), indicating the absence of structural defects or “hard lesions.”

**Molecular Mechanisms Involved in MHC Class I Downregulation**

In order to determine whether HDAC is implicated in the regulation of H-2 class I surface expression, GR9-C5 and -B11 clones were treated with TSA with the following results: in the GR9-C5 clone, TSA treatment produced a threefold increase in H-2 D\textsuperscript{d} molecule expression and a slight increase in H-2 K\textsuperscript{d} and L\textsuperscript{d} molecules; in the GR9-B11 clone, TSA treatment produced an increase of more than 16-fold in H-2 D\textsuperscript{d} molecule expression, 9.6-fold in H-2 L\textsuperscript{d} expression, and 1.8-fold in H-2 K\textsuperscript{d} molecule expression (Figure 2A).

Expression profiles revealed by mRNA next-generation sequencing were highly similar among the four tumor clones, which showed significant graded differences in the transcriptional expression of some genes related to antigen processing and presentation machinery and in the Fhit gene. Other differentially expressed genes showed no such graded differences in expression among the four tumor clones with varied MHC-I surface expressions. We also used flow cytometry to determine the expression of other markers involved in the immune response (PD-1, PD-L1, CD137L, CD137, TIM3, Galectin-9, Fas, and Fasl) finding no significant differences among these four tumor clones. The molecular mechanisms underlying the altered H-2

![Figure 2](image_url)
class I phenotypes in the GR9-B7, GR9-C5, and GR9-B11 clones involve the coordinated transcriptional downregulation of several APM components. Analysis by real-time RT-PCR showed that transcriptional expression of calreticulin, LMP-2, and LMP-7 genes was lower in GR9-B7 cells than in GR9-A7 cells. Tap-1, Tap-2, and tapasin were also downregulated in GR9-C5 cells, while calreticulin, LMP-2, Tap-1, and tapasin were downregulated in GR9-B11 cells (Figure 2B).

Our group previously reported the direct involvement of the Fhit tumor suppressor gene in the transcriptional regulation of APM components (16). The mRNA expression of Fhit in the GR9-A7 clone was 1.4-fold higher than in the GR9-B7 clone, around 3.6-fold higher than in the GR9-C5 clone, and 3.3-fold higher than in B11 cells (Figure 2C).

**H-2 Class I Phenotype Influences In Vivo Local Tumor Growth and Spontaneous Metastatic Capacity**

Assays were conducted at different cell doses, using the lowest dose (6.25 x 10^5 cells) to measure the local growth rate. Local tumors began to grow on day 8 in mice injected with GR9-C5 and -B11 cells and were removed on days 23 and 28, respectively, whereas they began to grow on days 14 and 16 postinjection, respectively, in those injected with GR9-A7 and -B7 cells and were removed on day 39 (Figure 3A).

Spontaneous metastasis assays were conducted to evaluate the *in vivo* metastatic potential. Ninety percent of mice injected with GR9 cells developed 2–9 pulmonary metastases (PM) and 0–1

**FIGURE 3** | (A) Cell lines with different patterns of H-2 class I expression show distinct local oncogenicity. Tumor clones were injected (6.25 x 10^5 cells) into the footpad of male BALB/c mice. The tumor diameter was measured three times/week and removed when it reached 10 mm. H-2 class I-positive tumors, GR9-A7 and -B7, grew more slowly than the more negative tumors GR9-C5 and -B11. The mean ± SD tumor diameter of 10 mice is shown as a function of time.

(B) Spontaneous metastasis assays with GR9-A7, -B7, -C5, and -B11 tumor clones. Four different cell doses (5 x 10^5, 25 x 10^5, 12.5 x 10^5, and 6.25 x 10^5 cells) were injected into the footpad of 10 mice each. The number of metastases per mouse was counted. GR9-B11 clone (MHC-I-negative) did not generate metastases at any tumor cell dose. GR9-A7, -B7, and -C5 clones all generated metastases. GR9-A7 clone (MHC-I-positive) showed the highest metastatic capacity (range, 1–52 metastases per mouse). *p < 0.05; **p < 0.01. Kruskal-Wallis test, followed by Dunn *post hoc* test was used for statistical analysis.
lymph node metastases (LNM). Each tumor cell clone was then injected at different doses (50 × 10^5, 25 × 10^5, 12.5 × 10^5, and 6.25 × 10^5 cells). As shown in Figure 3B, the highest spontaneous metastatic capacity was shown by GR9-A7 cells, which generated overt LNsMs and PMs (range, 1–52; 70–90% of the mice) at three of the four cell doses. Intermediate metastatic capacity was shown by GR9-B7 cells, which generated PMs (range, 1–6) at a cell dose of 25 × 10^5 (80% of mice) or 12.5 × 10^5 cells (20% of mice). A very low metastatic capacity was found for GR9-C5 cells, observing PMs (range, 1–3) in only 20% of animals. No overt metastases were produced at any dose by GR9-B11 (MHC-I-negative) cells, although hosts injected with this clone presented micrometastases in permanent immunodormancy (17). At necropsy, all of the mice injected with the highest dose (50 × 10^5 cells) were found to be overt metastasis-free, regardless of the tumor cell line used (data not shown). This may be attributable to the rapid growth of the local tumor, which was excised at 12 days after reaching a diameter of 10 mm. As mentioned above, the four tumor clones were classified into four groups according to their MHC-I cell surface expression, from highly positive to weakly positive. We analyzed the oncogenic and metastatic properties of a minimum of two clones per MHC-I group, finding that the results for the two clones were always completely reproducible. According to these in vivo assay findings, H-2 class I surface expression may be directly related to the metastatic capacity and inversely related to the local oncogenicity.

Changes in Immune Cell Subpopulations in Tumor-Bearing Mice

Host immune cell populations were analyzed on day 50 after tumor primary extirpation, when metastatic spread occurred. In lung-infiltrating lymphocytes, in comparison to wild-type mice, GR9 fibrosarcoma-bearing mice exhibited a strong decrease in several immune cell subpopulations, with a significant reduction (p < 0.05) in TCD3+ (36.1 vs. 51.9%), TCD8+ (6.5 vs. 9.7%), and TCD4+ (29.6 vs. 40.6%) lymphocytes; moreover, a significant increase in Treg cells was found (8.9 vs. 2.9% of CD4+ cells) (Table 1). Very similar results were also observed in GR9-B7 tumor-bearing mice, with a significant decrease (p < 0.05) in TCD3+ (42.3 vs. 51.9%), mainly TCD4+ (35.1 vs. 40.6%), and TCD8+ (7.2 vs. 9.7%) lymphocytes, and a significant increase in Treg cells (5.8 vs. 2.9% of CD4+) (Table 1). GR9-A7 tumor-bearing mice also showed a slight decrease in several immune cell subsets, with a reduction in TCD3+ lymphocytes vs. wild-type animals (43.3 vs. 51.9%) due to a decrease in TCD8+ (5.9 vs. 9.7%) and TCD4+ (37.4 and 40.6%) subpopulations; while a significant increase in Treg cells was observed (9.9 vs. 2.9% of CD4+). A strong increase in T lymphocytes was observed in GR9-B11 tumor-bearing mice, with a rise in TCD3+ lymphocytes (53.7 vs. 33.3%), due to an increase in T-helper (40.4 vs. 26.1%) and T-cytotoxic (13.0 vs. 6.9%) lymphocytes and a slight decrease in Treg cells (3.6 vs. 4.4%). Analysis of lymphocyte populations in peripheral blood from all mouse groups yielded the same results as observed in the spleen and the lungs (data not shown).

Anti-Metastatic Preclinical Assays with Immunotherapy and Chemoimmunotherapy Treatments

GR9, GR9-A7, and GR9-B7 were, therefore, selected as candidates to evaluate the response to anti-metastatic therapy. Injected cell doses were 12.5 × 10^6 cells for GR9 and the A7 clone and 25 × 10^6 cells for the B7 clone, i.e., doses at which these tumor cells exhibit high spontaneous metastatic capacity. Figure 4A depicts administration protocol of the four performed treatments (see Materials and Methods). The therapeutic strategies were as follows: (a) CpG+ irradiated cells for activation of tumor antigen presentation and of the T-cell immune response, focused on the recognition of tumor cells expressing tumor antigens; (b) PSK for activation of NK cells to recognize MHC-I low tumor cells (PSK may also increase T-cell subsets); (c) docetaxel for the comparison of chemoimmunotherapy with immunotherapy; and (d) PSK + docetaxel for comparison with the effects of PSK immunotherapy and docetaxel chemotherapy alone.

In the GR9-A7 group, metastases were detected in 9 of the 10 untreated mice (range 6–58 PMs; range 0–4 LNMs) and in 5 of those treated with docetaxel (2–9 PMs; 0–6 LNMs) (Figure 4B). By contrast, all of the 10 GR9-A7 mice treated with CpG+IR–TC, PSK, or PSK plus docetaxel were free of overt metastases at 50 days post-tumor extirpation (Figure 4B), and the other 10 mice in these groups were also metastasis-free after euthanasia on day 100 post-tumor extirpation (50 days after their last treatment). The GR9-B7 clone produced PMs in 7 of the 10 mice in the untreated group (range 1–4), whereas PMs were observed in only 3 of the 10 mice treated with PSK (2–3 PMs; 0–1 LNMs), 3 of the 10 mice treated with PSK plus docetaxel (2 PMs), and 2 of the 10 mice treated with docetaxel (range 1–8 PMs); however, metastases were detected in 8 out of the 10 mice treated with CpG + IR–TC (1–4 PMs; 0–1 LNMs), similar to the prevalence in untreated animals (Figure 4B). In comparison to the untreated GR9 group, the percentage of animals with metastases was only slightly reduced.
**TABLE 1 |** Changes in lung-infiltrating and splenic lymphocyte subpopulations.

| Lung lymphocyte subpopulations in tumor-bearing mice and wild-type |
|---------------------------------------------------------------|
| CD3+ | CD4+ | CD8+ | CD3+·CD4+·CD8+·FoxP3+ | CD3+·CD19+ | CD3+·CD49b+ | CD3+·CD49b+ |
| Wild-type | 51.9 ± 6.3 | 40.6 ± 5.5 | 9.7 ± 1.5 | 2.9 ± 0.7 | 35.2 ± 5.9 | 12.2 ± 0.9 | 1.8 ± 0.8 |
| GR9 | 36.1 ± 4.7* | 29.6 ± 2.4* | 6.5 ± 0.8* | 8.9 ± 2.1* | 49.1 ± 4.8* | 14.1 ± 0.6* | 1.4 ± 0.2 |
| GR9-A7 | 43.3 ± 4.1* | 37.4 ± 3.3 | 5.9 ± 1.1* | 9.8 ± 2.6* | 43.0 ± 6.0 | 12.0 ± 2.0 | 2.0 ± 0.5 |
| GR9-B7 | 42.3 ± 5.5* | 35.1 ± 4.0 | 7.2 ± 1.5 | 5.4 ± 1.1* | 43.2 ± 4.5 | 14.0 ± 0.7* | 2.4 ± 0.3* |
| GR9-B11 | 64.1 ± 5.2* | 50.5 ± 6.9 | 12.1 ± 2.2* | 3.5 ± 0.6 | 26.2 ± 2.1* | 9.6 ± 4.0 | 1.6 ± 0.3 |

| Splenic lymphocyte subpopulations in tumor-bearing mice and wild-type |
|---------------------------------------------------------------|
| CD3+ | CD4+ | CD8+ | CD3+·CD4+·CD8+·FoxP3+ | CD3+·CD19+ | CD3+·CD49b+ | CD3+·CD49b+ |
| Wild-type | 33.1 ± 4.3 | 26.1 ± 3.1 | 6.9 ± 1.8 | 4.4 ± 0.8 | 61.0 ± 4.2 | 4.6 ± 1.0 | 0.4 ± 0.3 |
| GR9 | 18.0 ± 1.6* | 14.6 ± 1.2* | 3.4 ± 0.5* | 10.6 ± 2.5* | 72.2 ± 5.8* | 9.6 ± 1.6* | 0.3 ± 0.2 |
| GR9-A7 | 30.3 ± 7.0 | 24.4 ± 5.3 | 5.8 ± 1.7 | 10.8 ± 4.2 | 65.5 ± 6.0 | 4.0 ± 2.0 | 0.9 ± 0.5 |
| GR9-B7 | 25.3 ± 7.4* | 19.7 ± 7.0* | 5.7 ± 1.5 | 6.9 ± 2.1* | 67.0 ± 9.5 | 7.7 ± 2.0* | 1.0 ± 0.4* |
| GR9-B11 | 53.7 ± 5.5* | 40.4 ± 4.1 | 13.0 ± 2.9 | 3.6 ± 1.7 | 41.0 ± 4.7* | 3.7 ± 1.0 | 1.4 ± 0.6* |

| Splenic lymphocyte subpopulations in tumor-bearing mice after immuno- or chemoimmunotherapy |
|---------------------------------------------------------------|
| CD3+ | CD4+ | CD8+ | CD3+·CD4+·CD8+·FoxP3+ | CD3+·CD19+ | CD3+·CD49b+ | CD3+·CD49b+ |
| GR9 Groups | CpG + GR9 | 19.9 ± 3.1 | 16.5 ± 2.8 | 3.3 ± 0.3 | 11.5 ± 2.9 | 75.3 ± 13.0* | 4.7 ± 0.7* | 0.2 ± 0.1* |
| | PSK | 32.1 ± 5.6* | 26.0 ± 4.4 | 6.2 ± 0.7* | 9.1 ± 1.1 | 61.8 ± 6.6* | 5.9 ± 1.6 | 0.4 ± 0.1 |
| | PSK + Docetaxel | 30.8 ± 3.4* | 19.7 ± 2.4 | 8.5 ± 2.8* | 10.1 ± 5.2 | 60.1 ± 5.1* | 8.9 ± 6.3* | 0.8 ± 1.1* |
| GR9-A7 Groups | CpG + A7 | 46.5 ± 5.3* | 31.9 ± 3.8 | 14 ± 2.2 | 4.7 ± 3.8 | 49.5 ± 12.4 | 3.8 ± 1.3 | 2.0 ± 0.8 |
| | PSK | 58.0 ± 17.5* | 44.2 ± 15.2 | 13.7 ± 2.4 | 9.5 ± 3.8 | 30.8 ± 15.5* | 11.1 ± 0.6* | 1.6 ± 0.1 |
| | PSK + Docetaxel | 36.6 ± 3.1* | 30.1 ± 2.2 | 6.5 ± 0.8 | 10.6 ± 0.3* | 60.2 ± 6.2 | 3.0 ± 0.1 | 0.9 ± 0.1* |
| GR9-B7 Groups | CpG + B7 | 21.6 ± 5.5 | 16.2 ± 5.4 | 5.5 ± 0.8 | 5.6 ± 1.8 | 73.7 ± 7.4 | 4.6 ± 1.7* | 0.8 ± 0.3* |
| | PSK | 32.2 ± 6.5 | 23.0 ± 6.0 | 7.6 ± 2.9 | 9.0 ± 2.5 | 62.4 ± 8.3 | 5.3 ± 1.6 | 0.7 ± 0.3 |
| | PSK + Docetaxel | 26.0 ± 7.14 | 20.6 ± 4.2 | 5.1 ± 3.2 | 9.6 ± 3.3 | 70.2 ± 5.7* | 3.6 ± 1.0* | 0.4 ± 0.3* |

Data are expressed as means ± SD.
*Percentage among CD4+ T cells.
*p < 0.05 compared with wild-type or untreated tumor-bearing mice.

from 90 to 70% by treatment with CpG + IR–TC, docetaxel, or PSK and to 80% by treatment with PSK + docetaxel. The mean metastasis count per mouse was lower in the mice receiving immunotherapy or chemoimmunotherapy but higher in those treated with docetaxel (Figure 4B).

**Changes in Immune Cell Subpopulations Generated in the Mice by the Different Treatments**

Host immune cell populations were determined 50 days after tumor primary extirpation, at 1 week after the end of the treatment. In the GR9-A7 groups, immunotherapy and chemoimmunotherapy each produced a significant (p < 0.05) increase in TCD3+ lymphocytes (46.5, 58.0, and 36.6 vs. 30.4%) and in CD4+ (31.9, 44.2, and 30.1 vs. 24.4%) and CD8+ (14, 13.7, and 6.5 vs. 5.8%) T-cell subsets in comparison to untreated tumor-bearing mice, with a decrease in Treg cells (4.7, 9.5, and 1.1 vs. 10.8%) (Table 1). Immunotherapy and chemoimmunotherapy protocols were completely effective to reverse the alterations in immune cell subsets promoted by the GR9-A7 tumor clone and abrogate the metastatic colonization.

In GR9-B7 tumor-bearing mice, treatments with PSK and PSK plus docetaxel produced a slight recovery in TCD3+ (32.2 and 26.0 vs. 25.3%, respectively) due to an increase in CD4+ lymphocytes (23.0 and 20.6% vs. 19.7%) vs. untreated tumor-bearing mice, but a significant increase in Treg cells (9.0 and 9.6 vs. 6.9%) was also observed (Table 1). Hence, the immune status was not completely reversed with immunotherapy and chemoimmunotherapy treatments of GR9-B7 groups, with only a partial decrease in metastasis colonization. In contrast, treatment with CpG+IR–TC was completely ineffective. In the GR9 tumor-bearing mouse group, immunotherapy with PSK and chemoimmunotherapy with PSK + docetaxel partially reversed the alterations in immune cell subsets generated by GR9 tumor cells, producing a significant increase in CD3+ T lymphocytes (32.1 and 30.8 vs. 18.0%, respectively) due to an increase in TCD4+ (26.0 and 19.7 vs. 14.6%) and TCD8+ (6.2 and 8.5 vs. 3.4%) lymphocytes. In brief, none of the treatments was able to completely reverse the alterations in immune cell subsets in GR9 and GR9-B7 mice groups, unlike in the GR9-A7 group. Analysis of lymphocyte subpopulations in peripheral blood yielded similar results (data not shown).

**Generation of a New Diversity in MHC-I Expression on Metastases**

The spontaneous metastases derived from GR9, GR9-A7, GR9-B7, and GR9-C5 exhibited a second heterogeneity in MHC-I cell surface expression. Metastases were classified into four types according to the relationship of their H-2 surface expression with that of the corresponding tumor clone: Phenotype I, with similar H-2 expression to that of the injected tumor cells; Phenotype II, with reversible downregulation of all three H-2 molecules; Phenotype III, with partial downregulation of all three H-2 molecules and total and reversible loss of H-2 D4 and/or H-2 L4.
molecules; and Phenotype IV, with partial and reversible down-regulation of H-2 Kd and Dd molecules and total irreversible loss of H-2 Ld allele. Reversible or irreversible defects were defined by the induction or non-induction of surface expression of each H-2 allele after IFN-γ treatment. Phenotype I was recorded for 4% of GR9-derived spontaneous metastases, phenotype II for 83%, and phenotype III for 13% (Figure 5A). Phenotype I was recorded for 50% of spontaneous metastases derived from the GR9-A7 tumor cell clone, phenotype II for 12.5%, and phenotype III for 37.5% (Figure 5B). Among metastases derived from GR9-B7 cell clone, 69.2% were classified as phenotype I, 23.1% as phenotype III, and 7.7% as phenotype IV (Figure 5C). The H-2 class I expression of all metastases from GR9-C5 clone was the same as that of the original clone (data not shown). MHC-I expression was highest in metastases derived from GR9-A7 clone, followed by metastases from GR9-B7 clone, and was lowest in those derived from GR9 tumor cells.

**Experimental Metastatic Potential of These Tumor Cell Clones**

The experimental metastasis assay protocol completely differed from that of the spontaneous metastasis assays, directly injecting tumor cells into the blood stream and thereby excluding initial stages of local tumor growth and extravasation. GR9-A7 and B11 clones were selected for experimental metastatic assay because of their differences in H-2 class I expression. At day 30 post-cell injection, necropsy showed that 100% of mice injected with GR9-A7 cells were metastasis-free, whereas 80% of mice injected with GR9-B11 presented overt metastases (Table 2). These findings are the opposite of the spontaneous metastasis results.

**DISCUSSION**

Intratumoral genetic heterogeneity has been widely reported in cancer and can determine the biological characteristics and progression of tumors (18–20). However, reversible phenotypic intratumoral heterogeneity may also be important (21, 22). The present results indicate that intratumoral heterogeneity in the MHC-I cell surface expression (MHC-I phenotype) of a tumor may determine its oncogenic potential, metastatic capacity, and response to immunotherapy (Figure 6). Cell clones isolated from a MCA-induced primary fibrosarcoma in BALB/c mice had a wide range of MHC-I phenotypes, from negative to highly positive. MHC-I downregulation was observed in some clones but was reversible after IFN-γ treatment (soft MHC-I lesions). Coordinated transcriptional downregulation of APM genes is responsible for these alterations in MHC-I surface expression.
Our group previously reported that loss of expression of the Fhit tumor suppressor gene may be responsible for the transcriptional downregulation of APM components (16), and the present results show the loss of Fhit transcriptional expression in clones with low MHC-I phenotype. Alterations in MHC-I surface expression are attributable to epigenetic mechanisms, given that expression was restored after TSA treatment.

Examination of the in vivo biological behavior of the cell clones revealed an inverse correlation between MHC-I phenotype and local oncogenicity, finding a higher local tumor growth rate for
clones with lower MHC-I expression (Figure 6) (23). In addition, Fhit gene transfection of the MHC-I-negative GR9-B11 clone completely reversed the MHC-I downregulation, transforming it into a highly immunogenic and non-oncogenic clone and this immunorejection was mediated by CD8+ T lymphocytes (manuscript in preparation). We previously reported that total loss of HLA expression generated more oncogenic tumor cells in human tumors and that transfection of one lost HLA allele reverted these oncogenic properties, showing that MHC-I molecules may act as tumor suppressor genes (8, 11). Taken together, these results indicate that the loss of MHC-I expression or of genes co-regulated with MHC expression may contribute to increased local oncogenicity. By contrast, the in vivo spontaneous metastatic potential was greater in clones with high MHC-I expression than in those with low MHC-I expression, showing a direct correlation with the MHC-I profile (Figure 6). Hence, the spontaneous metastatic capacity cannot always be extrapolated from the local oncogenicity or vice-versa, and they may change in opposite directions. According to this finding, the approach to a localized primary tumor may not be appropriate for advanced metastatic disease.

Analysis of the immune cell populations in tumor-bearing mice showed that the highly metastatic (MHC-I positive) tumor cell clones induced a strong decrease in several immune cell subsets in the host. Given that these clones and their metastases are MHC-I positive, this decrease might be attributable to an immune escape mechanism. The same may occur in patients with MHC-I positive tumors, allowing tumor cells to progress and avoid their destruction. If this decrease can be reversed, their MHC-I positive metastases might be recognized by the immune system. Thus, GR9-A7 and their metastases showed the highest MHC-I positivity, but immunotherapy completely reversed the decrease in immune subpopulations and halted metastatic dissemination in GR9-A7 tumor-bearing mice (24). By contrast, immunotherapy partially reverted the decrease in immune cell subsets and also partially reverted metastatic dissemination in mice bearing tumors from the GR9-B7 tumor clone, which showed intermediate MHC-I expression, as did its metastases. A strong decrease in T lymphocytes and a strong increase in Treg cells were observed in mice bearing tumors from GR9 tumor cells, which include all four tumor cell clones, and the overt metastases detected had the lowest MHC-I surface expression. In these animals, the immunotherapy did not reverse these changes in immune subpopulations or halt metastatic progression. In the mice bearing tumors from the MHC-I negative GR9-B11 tumor

| TABLE 2 | Experimental metastasis assays with GR9-A7 and GR9-B11 tumor cell clones. |
|---------|-----------------|-----------------|------------------|-----------------|
| **Cell lines** | **Cell dose** | **Number of mice** | **Mice with metastases** | **Number of metastases** |
| | | | | **Micro-PMs** | **Macro-PMs** |
| GR9-A7 | $2.5 \times 10^5$ | 10 | 0/10 | 0 | 0 |
| GR9-B11 | $2.5 \times 10^5$ | 10 | 8/10 | 2–6 | 1–4 |

*Micro-PMs: pulmonary micrometastases.
*Macro-PMs: pulmonary macrometastases.

**FIGURE 6** | Influence of MHC-I and Fhit expression in primary tumors on their oncogenic and metastatic potential and response to immunotherapy.
cell clone, a strong immunostimulation was produced, with no
detection of overt metastases during follow-up; however, overt
metastases appeared after these animals were depleted of CD8+ T
lymphocytes, indicating that the immune response mediated
by CD8+ T lymphocytes kept the metastases in a permanent
dormant state (17). Interestingly, these dormant metastases
presented a MHC-I positive phenotype. According to these
findings, the metastasis prognosis is worse for highly MHC-I
positive tumor cell clones, but they may respond very well to
immunotherapy, to which tumors with intermediate MHC-I
phenotype do not fully respond. The metastatic prognosis may be
good for MHC-I negative tumor clones in some cases, producing
MHC-I positive metastases in an immunodormancy state medi-
at by TCD8+ lymphocytes (Figure 6). In brief, the MHC-I
phenotype of cancer cells and the host immune status, especially
in relation to T lymphocytes, may determine the response of
metastases to immunotherapy. It may, therefore, be of interest
to diagnose the MHC-I phenotype of cancer cells and the T-cell
subsets of cancer patients before ordering immunotherapy (25).
Patients with MHC-I positive tumors or metastases who show
low T-cell subsets may be good candidates for immunotherapy
(26, 27). Likewise, in certain types of human cancer, absent or
positive MHC-I expression on primary tumor cells is a marker of
good prognosis, whereas a moderate downregulation of MHC-I
expression is not. Thus, the highly positive expression of MHC-I
molecules or their total loss have been associated with a better
prognosis in colorectal tumors (28, 29) while downregulation
of APM component and HLA-I expression has been associated
with shorter recurrence free and overall survival in cervical
cancer and triple-negative breast cancer patients (30, 31). Recent
studies revealed that detection of HLA class I and CD8+ T-cell
infiltration is a good prognostic marker of the clinical outcome
in ovarian cancer and biliary tract cancer (26, 32). Total loss of
MHC-I expression was found to be an independent indicator of
a good prognosis in breast cancer (33), and HLA class I and Treg
levels were reported to predict the response to chemotherapy in
early breast cancer (27).

During the metastatic process, a new heterogeneity in
MHC-I phenotypes was observed, finding differences in MHC-I
phenotype between the overt metastases and the tumor clone
from which they derived. In all cases, a downregulation in
MHC-I phenotype was observed in >45% of overt metastases.
In the case of GR9 tumor cells, 96% of the metastases showed a
decrease in MHC-I phenotype, which might explain the failure
of immunotherapy in these mice. By contrast, metastases from
the GR9-A7 tumor clone had a high MHC-I phenotype, and the
immunotherapy was completely effective. The metastases from
GR9-B7 had an intermediate MHC-I positive phenotype, and the
immunotherapy was partially effective. It, therefore, appears that
the MHC-I phenotype of metastases might determine the effec-
tiveness of immunotherapy. Activation of the immune system
by immunotherapy might be effective and enduring if immune
cells are able to recognize MHC-I positive metastatic cells.
The downregulation or selective loss of HLA-I expression vs. the
primary tumor has been observed in LNM from humans with breast,
colorectal, gastric, laryngeal, cervical, or head and neck cancers,
suggesting an association between the loss of HLA-I molecules
and lymph node metastasis (34–38). Loss of MHC-I cell surface
expression has also been described in progressive metastases
from melanoma after immunotherapy (39), and MHC-I down-
regulation in cancer cells was recently reported to be a driver of
resistance to chemotherapy and immunotherapy in patients with
melanoma or prostate cancer (40–42).

Interestingly, none of the tumor cell clones under study had in vivo spontaneous metastatic potential when 5 million cells
were injected, including clones showing high spontaneous meta-
static potential at lower cell doses. The size of all excised primary
tumors was the same (largest diameter of 10 mm), regardless
of the cell dose, indicating that metastatic dissemination is
influenced not only by tumor size but also by the time period
of local tumor growth. In the present study, metastatic colonization
was achieved at tumor cell doses, when the growth of primary
tumors was slower. The role of early-disseminated tumor cells in
metastatic progression at a secondary site is a controversial issue
(43–47). Our data suggest that GR9 tumor cell clones cannot
initiate metastatic colonization at secondary sites over the short
term.

A striking finding in our cancer model was the inverse
correlation between spontaneous and experimental metastatic
potential, with higher experimental metastatic capacity being
found for the clones with lower MHC-I expression. In other
words, one tumor cell clone may present high spontaneous meta-
static potential and null experimental metastatic potential and
another may present null spontaneous metastatic potential and
high experimental metastatic potential. Spontaneous metastasis
assays faithfully resemble metastatic process in human cancers
from primary local tumor to secondary colonization (48, 49).
However, primary tumor cells are injected directly into the
bloodstream in experimental metastasis assays, so that not all of
the sequential steps in the metastatic cascade are reproduced.
Experimental metastatic assays are frequently used to evaluate
the metastatic potential of a primary tumor and the effectiveness
of anti-metastatic treatments. However, our findings suggest that
these assays may fail to reproduce the metastatic advance
of the disease and the response to pharmacological therapies in
preclinical animal models.

In summary, an individual cancer should be considered as
heterogeneous, comprising different tumor and metastasis cell
clones that may determine the metastatic progression, antitumor
immunosurveillance, and response to immunotherapy. The
development of precise tumor targeting strategies, therefore,
requires elucidation of the tumor and metastatic subpopulations
of a given cancer. Our proposed tumor model represent a first
step in understanding how the presence of different MHC-I
phenotypes of cell clones in the primary tumor can influence
the success or failure of antitumor treatments. Levels of MHC-I
expression on cancer cells may modulate the oncogenicity, meta-
static progression, and response to immunotherapy. The present
results suggest that a high MHC-I phenotype of the primary
tumor and metastases predict a good anti-metastatic response to
immunotherapy. The MHC-I phenotype on primary tumors and
metastases and the T immune cell subsets of the patient may serve
as predictive markers of both the prognosis and the response to
immunotherapy.
REFERENCES

1. Zhang J, Fujimoto J, Wedge DC, Song X, Seth S, Chow CW, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science (2014) 346(6206):256–9. doi:10.1126/science.1256930
2. Deb D, Rajaram S, Larsen JE, Dosypay PD, Marullo R, Li LS, et al. Combination therapy targeting BCL6 and phospho-STAT3 defeats intratumor heterogeneity in a subset of non-small cell lung cancers. Cancer Res (2017) 77(11):3070–81. doi:10.1158/0008-5472.CAN-15-3052
3. Stravenga G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med (2016) 21(7):795–801. doi:10.1038/nm.3870
4. McGowan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell (2017) 168(4):613–28. doi:10.1016/j.cell.2017.01.018
5. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science (2013) 339(6127):1546–58. doi:10.1126/science.1235122
6. Segbágh M, Allard MA, Bosselut N, Dao M, Vibeert E, Lewin M, et al. Evidence of intermetastatic heterogeneity for pathological response and genetic mutations within colorectal liver metastases following preoperative chemotherapy. Oncotarget (2016) 7(16):21591–600. doi:10.18632/oncotarget.7809
7. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoeediting and its three component phases – elimination, equilibrium and escape. Curr Opin Immunol (2014) 27:16–25. doi:10.1016/j.coi.2014.01.004
8. Garrido C, Algarra I, Maleno I, Stefanski J, Collado A, Garrido F, et al. Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. Cancer Immunol Immunother (2009) 59(1):13–26. doi:10.1007/s00262-009-0716-5
9. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumor development. Immunol Today (1993) 14(10):491–9. doi:10.1016/0167-5699(93)90264-L
10. Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot MA, Ruiz-Cabello F, García-Lora AM. Generation of MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol (2007) 256:139–89. doi:10.1016/S0077-7869(07)56005-5
11. Garrido C, Paco L, Romero I, Berrugueta E, Stefanski I, Collado A, Garrido F, et al. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis (2012) 33(3):687–93. doi:10.1039/carin/bgr318
12. Garrido F, Cabrera T, Aptsiauri N. “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer (2010) 127(2):249–56. doi:10.1002/ijc.25270
13. Garrido A, Perez M, Delgado C, Garrido ML, Rojano I, Algarra I, et al. Influence of class I H-2 gene expression on local tumor growth. Description of a model obtained from clones derived from a solid BALB/c tumor. Exp Clin Immunogenet (1986) 3(2):98–110.
14. Akagi J, Baba H. PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients. Int J Clin Oncol (2010) 15(4):145–52. doi:10.1007/s10147-010-0033-1
15. Lu H, Yang Y, Gad E, Wenner CA, Chang A, Larson ER, et al. Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res (2011) 17(1):67–76. doi:10.1158/1078-0432.CCR-10-1763
16. Romero I, Martinez M, Garrido C, Collado A, Algarra I, Garrido F, et al. The tumor suppressor Fhit positively regulates MHC class I expression on cancer cells. J Pathol (2012) 227(3):367–79. doi:10.1002/path.4029
17. Romero I, Garrido C, Algarra I, Collado A, Garrido F, Garcia-Lora AM. T lymphocytes restrain spontaneous metastases in permanent dormancy. Cancer Res (2014) 74(7):1955–68. doi:10.1158/0008-5472.CAN-13-2084
18. Zhang LL, Kan M, Zhang MM, Yu SS, Xie HJ, Gu ZH, et al. Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer. Int J Cancer (2016) 140(1):103–8. doi:10.1002/ijc.30437
19. Gyanchandani R, Lin Y, Lin HM, Cooper K, Normolle DP, Bruafsky A, et al. Intratumor heterogeneity affects gene expression profile test prognostic risk stratification in early breast cancer. Clin Cancer Res (2016) 22(11):5362–9. doi:10.1158/1078-0432.CCR-15-2889
20. McCreery MQ, Halliwill KD, Chin D, Delrosario R, Hass R, Vuong P, et al. Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers. Nat Med (2015) 21(12):1514–20. doi:10.1038/nm.3979
21. Quek KL, Li J, Estecio M, Zhang J, Fujimoto J, Roarty E, et al. DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. Oncotarget (2017) 8(13):21994–2002. doi:10.18632/oncotarget.15777
22. Brocks D, Assenov Y, Minner S, Bogatyrova O, Simon R, Koop C, et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep (2014) 8(3):798–806. doi:10.1016/j.celrep.2014.06.053
23. Garrido F, Romero I, Aptsiauri N, Garcia-Lora AM. Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype. Int J Cancer (2016) 138(2):271–80. doi:10.1002/ijc.29375
24. Garrido C, Romero I, Berrugueta E, Cancela B, Algarra I, Collado A, et al. Immunotherapy eradicates metastases with reversible defects in MHC class I expression. Cancer Immunol Immunother (2011) 60(9):1257–68. doi:10.1007/s00262-011-1027-1
25. Garrido F, Aptsiauri N, Douroiuin EM, Garcia-Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol (2016) 39:44–51. doi:10.1016/j.coi.2015.12.007
26. Hirohashi Y, Torigoe T, Mariya T, Kochin V, Saito T, Sato N. HLA class I as a predictor of clinical prognosis and CTL infiltration as a predictor of

AUTHOR CONTRIBUTIONS

IR, FG, and AG-L: design and supervision of the study, and writing and revising the manuscript. IR, CG, IA, VC, AC, and AG-L: development of methodology, acquisition of data and analysis, and interpretation of data. All authors revised the manuscript, approved the final version, and agreed to be accountable for the work.

ACKNOWLEDGMENTS

The authors thank I. Linares, A. B. Rodriguez, and E. Arias for technical advice and R. Davies for editorial assistance.

FUNDING

This work was supported by grants cofinanced by FEDER funds (EU) from the Instituto de Salud Carlos III (PI 11/01022, PI12/02031, PI14/01978, PI15/00528, and PT13/0010/0039), Worldwide Cancer Research project 15-1166, Junta de Andalucía (Group CTS-143, CTS-3952, CVI-4740 grants) and European Community (LSHC-CT-2004-503306, OJ 2004/c158, 18234). AG-L was supported by Contract I3-SNS from Junta de Andalucía and ISCIII, IR by Rio-Hortega Contract CM12/0033 from ISCIII, and CG by FPU–MEC1631.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations of European Community Directive 86/609/CEE and Spanish law (Real Decreto 1201/2005) on the use of laboratory animals, and their housing and the experimental procedures were approved by the Junta de Andalucía animal care committee and adhered to animal welfare guidelines of the National Committee for Animal Experiments.
chemosensitivity in ovarian cancer. *Oncoimmunology* (2015) 4(5):e1005507. doi:10.1080/2162402X.2015.1005507

27. de Kruijf EM, van Nes JC, Sajet A, Tummers QR, Putter H, Osanto S, et al. The predictive value of HLA class I tumor expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. *Clin Cancer Res* (2010) 16(4):1272–80. doi:10.1186/1078-0432.CCR-09-1844

28. Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. *Int J Cancer* (2006) 118(1):6–10. doi:10.1002/ijc.21303

29. Iwayama Y, Tsuruma T, Mizuguchi T, Furuhata T, Toyota N, Matsumura M, et al. Prognostic value of HLA class I expression in patients with colorectal cancer. *World J Surg Oncol* (2015) 13:36. doi:10.1186/s12957-015-0456-2

30. Jordanova ES, Gorton A, Ayachi O, Prins F, Durrant LG, Kenter GG, et al. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+regulatory T-cell ratio: which variable determines survival of cervical cancer patients? *Clin Cancer Res* (2008) 14(7):2028–35. doi:10.1158/1078-0432.CCR-07-4554

31. Pedersen MH, Hood BL, Beck HC, Conrads TP, Ditzel HJ, Leth-Larsen R. Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors. *Oncoimmunology* (2017) 6(5):e1305531. doi:10.1080/2162402X.2017.1305531

32. Goepert B, Frauenshchu L, Zucknick M, Roessler S, Mehrabi A, Hafezi M, et al. Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. *Br J Cancer* (2015) 113(9):1343–9. doi:10.1038/bjc.2015.337

33. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. *Int J Cancer* (2005) 117(2):248–55. doi:10.1002/ijc.21163

34. Yoshi M, Tanaka H, Ohira M, Muguruma K, Sakurai K, Kubo N, et al. Association of MHC class I expression and lymph node metastasis of gastric carcinoma. *Hepatogastroenterology* (2013) 60(123):611–5. doi:10.5755/hge12433

35. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated to poor outcome in triple-negative breast cancer patient tumors. *Oncoimmunology* (2017) 6(5):e1305531. doi:10.1080/2162402X.2017.1305531

36. Jordanova ES, Gorton A, Ayachi O, Prins F, Durrant LG, Kenter GG, et al. Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. *Br J Cancer* (2015) 113(9):1343–9. doi:10.1038/bjc.2015.337

37. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. *Int J Cancer* (2005) 117(2):248–55. doi:10.1002/ijc.21163

38. Yoshi M, Tanaka H, Ohira M, Muguruma K, Sakurai K, Kubo N, et al. Association of MHC class I expression and lymph node metastasis of gastric carcinoma. *Hepatogastroenterology* (2013) 60(123):611–5. doi:10.5755/hge12433

39. Carretero R, Wang E, Rodriguez AL, Reinboth J, Ascierto ML, Engle AM, et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. *Int J Cancer* (2011) 131(2):387–95. doi:10.1002/ijc.26471

40. Domingo-Domench J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinna SA, Rodriguez-Barrueco R, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of Notch- and Hedgehog-dependent tumor-initiating cells. *Cancer Cell* (2012) 22(3):373–88. doi:10.1016/j.ccr.2012.07.016

41. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogova M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. *Nature* (2012) 490(7420):412–6. doi:10.1038/nature11538

42. del Campo AB, Kyte JA, Carretero J, Zinchenco S, Mendez R, Gonzalez-Aseguinolaza G, et al. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. *Int J Cancer* (2014) 134(1):102–13. doi:10.1002/ijc.28338

43. Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. *J Clin Invest* (2010) 120(6):2030–9. doi:10.1172/JCI42002

44. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. *Cancer Cell* (2008) 13(1):58–68. doi:10.1016/j.ccc.2007.12.003

45. Harper KL, Sosa MS, Entenberg D, Nobre R, et al. Mechanism of early dissemination and metastasis in Her2+ mammary cancer. *Nature* (2016) 540:588–92. doi:10.1038/nature20609

46. Hosseini H, Obradovic MM, Hoffmann M, Harper KL, Sosa MS, Werner-Klein M, et al. Early dissemination seeds metastasis in breast cancer. *Nature* (2016) 540:552–8. doi:10.1038/nature20785

47. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature* (2010) 467(7319):1114–7. doi:10.1038/nature09515

48. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced melanoma. *Curr Opin Pharmacol* (2010) 10(5):571–7. doi:10.1016/j.coph.2010.06.003

Conflict of Interest Statement: The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Romero, Garrido, Algarra, Chamorro, Collado, Garrido and Garcia-Lora. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.